Activation state egfr and STAT-3 as prognostic markers in resected non-small cell lung cancer

Lung Cancer

Volumn 55, Issue 3, 2007, Pages 349-355

  Cortas, Tania ^a   Eisenberg, Rosana ^b   Fu, Pingfu ^a   Kern, Jeffrey ^b   Patrick, Lauren ^c   Dowlati, Afshin ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

EGFR; Lung cancer; Prognosis; STAT 3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; STAT3 PROTEIN;

ADULT; AGE; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENDER; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STAINING; TIME SERIES ANALYSIS; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 33847409232     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.11.003     Document Type: Article

References (30)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
3. Strauss G.M. Prognostic markers in resectable non-small cell lung cancer. Hematol Oncol Clin North Am 11 (1997) 409-434
4. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
5. Buettner R., Mora L.B., and Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8 (2002) 945-954
6. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
7. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
8. Song L., Turkson J., Karras J.G., Jove R., and Haura E.B. Activation of STAT-3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22 (2003) 4150-4165
9. Wells A. The epidermal growth factor receptor (EGFR) a new target for cancer therapy. Signal 1 (2000) 4-11
10. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur J Cancer 37 Suppl 4 (2001) S9-S15
11. Dazzi H., Hasleton P.S., Thatcher N., Barnes D.M., Wilkes S., Swindell R., et al. Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer 59 (1989) 746-749
12. Rusch V., Baselga J., Cordon-Cardo C., Orazem J., Zaman M., Hoda S., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53 10 Suppl (1993) 2379-2385
13. Pfeiffer P., Clausen P.P., Andersen K., and Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 74 (1996) 86-91
14. Pastorino U., Andreola S., Tagliabue E., Pezzella F., Incarbone M., Sozzi G., et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15 (1997) 2858-2865
15. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., and Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3 (1997) 515-522
16. Pfeiffer P., Nexo E., Bentzen S.M., Clausen P.P., Andersen K., and Rose C. Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis. Br J Cancer 78 (1998) 96-99
17. Brabender J., Danenberg K.D., Metzger R., Schneider P.M., Park J., Salonga D., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7 (2001) 1850-1855
18. Cox G., Jones J.L., and O'Byrne K.J. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 6 (2000) 2349-2355
19. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21 (2003) 3798-3807
20. O'Byrne K.J., Cox G., Swinson D., Richardson D., Edwards J.G., Lolljee J., et al. Towards a biological staging model for operable non-small cell lung cancer. Lung Cancer 34 suppl 2 (2001) S83-S89
21. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
22. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
23. Cianfrocca M., and Goldstein L.J. Prognostic and predictive factors in early-stage breast cancer. Oncologist 9 (2004) 606-616
24. Zheng Z, Bepler G, Cantor A, Haura EB. Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer, 2005;128:308-16.
25. Kanematsu T., Yano S., Uehara H., Bando Y., and Sone S. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 13 (2003) 289-298
26. Mukohara T., Kudoh S., Yamauchi S., Kimura T., Yoshimura N., Kanazawa H., et al. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 41 (2003) 123-130
27. Haura E.B., Zheng Z., Song L., Cantor A., and Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11 (2005) 8288-8294
28. Kusaba T., Nakayama T., Yamazumi K., Yakata Y., Yoshizaki A., Inoue K., et al. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15 (2006) 1445-1451
29. Horiguchi A., Oya M., Shimada T., Uchida A., Marumo K., and Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 168 (2002) 762-765
30. Berclaz G., Altermatt H.J., Rohrbach V., Siragusa A., Dreher E., and Smith P.D. EGFR dependent expression of STAT-3 (but not STAT1) in breast cancer. Int J Oncol 19 (2001) 1155-1160